Skip to ContentSkip to Navigation
About us Latest news Press information

Frijlink, Prof. Erik

Erik Frijlink
Erik Frijlink

Erik Frijlink (1960, Meppel) has been professor of Pharmaceutical Technology and Biopharmacy at the University of Groningen since 1998. Prior to this, he was head of the Pharmaceutical Development department at Solvay Pharmaceuticals. His research group focuses on advanced technologies to improve the administration of medicines and is internationally prominent in this area.

At least 600,000 patients currently use an inhaler invented by the team around Frijlink. ‘And that number is headed towards one million. It’s great when you are able to develop a product that can help patients’, Frijlink says. The Novolizer is a powder inhaler that allows asthma patients, for example, to get medication into their lungs. The secret of the inhaler lies within the cyclone it contains, a chamber in which the medicine spins rapidly, driven by the patient’s inhalation force.

Frijlink is head of an international consortium that is searching for a universal flu vaccine in a research project in which twelve international partners are participating. The European Union supports the research with a EUR 6 million grant. Frijlink is confident that a vaccine protecting people from all types of flu will be found in the near future, making the annual flu jab redundant. Frijlink is particularly enthusiastic about drugs that can be administered via an inhaler, as these could be more effective than injections.

Erik Frijlink was nominated for the Huibregtsen Prize 2016. The jury report says: ' Frijlink’s work is a textbook example of ground-breaking research that is also of great importance to society. He combines academic excellence with social relevance, while also being the inventor one of only a handful of discoveries by a Dutch university leading to a remarkable flow of patent-generated income.'

Previously in the news

Article NOS
Article NOS

2024

Nguyen, K. T. T., Zillen, D., Lasorsa, A., van der Wel, P. C. A., Frijlink, H. W., & Hinrichs, W. L. J. (2024). Combinations of arginine and pullulan reveal the selective effect of stabilization mechanisms on different lyophilized proteins. International Journal of Pharmaceutics, 654, Article 123938. https://doi.org/10.1016/j.ijpharm.2024.123938
Janssen, P. H. M., Fathollahi, S., Dickhoff, B. H. J., & Frijlink, H. W. (2024). Critical review on the role of excipient properties in pharmaceutical powder-to-tablet continuous manufacturing. Expert Opinion on Drug Delivery, 21(7), 1069-1079. https://doi.org/10.1080/17425247.2024.2384698
Heida, R., Jacob Silva, P. H., Akkerman, R., Moser, J., de Vries-Idema, J., Bornet, A., Pawar, S., Stellacci, F., Frijlink, H. W., Huckriede, A. L. W., & Hinrichs, W. L. J. (2024). Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 204, Article 114507. https://doi.org/10.1016/j.ejpb.2024.114507
de Jong, L., Luinstra, M., Aalbers, A. F., Wijma-Vos, A. J., D’Angremont, E., van der Meulen, A. A. E., Rutgers, A. W. F., Steenhuis, L., Hagedoorn, P., van Laar, T., & Frijlink, H. W. (2024). Therapeutic effect of an inhaled levodopa dry powder formulation on off episodes in patients with Parkinson's disease. Therapeutic advances in neurological disorders, 17. https://doi.org/10.1177/17562864241289207

2023

Otten, A. T., van der Meulen, H. H., Steenhuis, M., Loeff, F. C., Touw, D. J., Kosterink, J. G. W., Frijlink, H. W., Rispens, T., Dijkstra, G., Visschedijk, M. C., & Bourgonje, A. R. (2024). Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 30(3), 325–335. https://doi.org/10.1093/ibd/izad103
van der Kooij, R. S., Beukema, M., Huckriede, A. L. W., Zuidema, J., Steendam, R., Frijlink, H. W., & Hinrichs, W. L. J. (2023). A Single Injection with Sustained-Release Microspheres and a Prime-Boost Injection of Bovine Serum Albumin Elicit the Same IgG Antibody Response in Mice. Pharmaceutics, 15(2), Article 676. https://doi.org/10.3390/pharmaceutics15020676
Frijlink, H., Lagarce, F., Touw, D., & Woerdenbag, H. (2023). Biopharmaceutics. In P. Le Brun, S. Crauste-Manciet, I. Krämer, J. Smith, & H. Woerdenbag (Eds.), Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products, Second Edition (pp. 67-91). Springer International Publishing AG. https://doi.org/10.1007/978-3-031-20298-8_5
Ahmed, A. A., Otten, A. T., Gareb, B., Huijmans, J. E., Eissens, A. C., Rehman, A., Dijkstra, G., Kosterink, J. G. W., Frijlink, H. W., & Schellekens, R. C. A. (2023). Capsules with Ileocolonic-Targeted Release of Vitamin B2, B3, and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process. Pharmaceutics, 15(5), Article 1354. https://doi.org/10.3390/pharmaceutics15051354
Nugrahadi, P. P., Hinrichs, W. L. J., Frijlink, H. W., Schöneich, C., & Avanti, C. (2023). Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics, 15(3), Article 15030935. https://doi.org/10.3390/pharmaceutics15030935
Heida, R., Akkerman, R., Silva, P. H. J., Lakerveld, A., Ortiz, D., Bigogno, C., Gasbarri, M., Van Kasteren, P. B., Stellacci, F., Frijlink, H. W., Huckriede, A., & Hinrichs, W. (2023). Development of an inhalable antiviral powder formulation against respiratory syncytial virus. Journal of Controlled Release, 357(5), 264-273. https://doi.org/10.1016/j.jconrel.2023.03.059
Otten, A. T., Peters, V., Barth, I., Stevens, C. L., Bourgonje, A. R., Frijlink, H. W., Harmsen, H. J. M., Rehman, A., Campmans-Kuijpers, M. J. E., & Dijkstra, G. (2023). Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn's disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial. BMJ Open, 13(3), Article e069654. https://doi.org/10.1136/bmjopen-2022-069654
Heida, R., Frijlink, H. W., & Hinrichs, W. L. J. (2023). Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: Reasons to prioritize the pulmonary route of administration. mBio, 14(5), Article e0129523. https://doi.org/10.1128/mbio.01295-23
Mahri, S., Wilms, T., Hagedorm, P., Guichard, M. J., Vanvarenberg, K., Dumoulin, M., Frijlink, H., & Vanbever, R. (2023). Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study. European Journal of Pharmaceutical Sciences, 189, Article 106522. https://doi.org/10.1016/j.ejps.2023.106522
Frijlink, H. W., Eissens, A. C., van Goor, H., Mulder, D. J., & Joles, J. A. (2023). Oral dosage forms of a therapeutically active acid-labile salt and methods and uses related thereto. (Patent No. WO2023140729).
Heida, R., Hagedoorn, P., Van Meel, M. C., Prins, R., Simonis, F., Akkerman, R., Frijlink, H. W., Huckriede, A., de Boer, A., & Hinrichs, W. (2023). Performance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice. Pharmaceutics, 15(7), Article 1847. https://doi.org/10.3390/pharmaceutics15071847
Nguyen, K. T. T., Zillen, D., van Heijningen, F. F. M., van Bommel, K. J. C., van Ee, R. J., Frijlink, H. W., & Hinrichs, W. L. J. (2023). Surface Engineering Methods for Powder Bed Printed Tablets to Optimize External Smoothness and Facilitate the Application of Different Coatings. Pharmaceutics, 15(9), Article 2193. https://doi.org/10.3390/pharmaceutics15092193

2022

van der Kooij, R. S., Steendam, R., Frijlink, H. W., & Hinrichs, W. L. J. (2022). An overview of the production methods for core-shell microspheres for parenteral controlled drug delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 170, 24-42. https://doi.org/10.1016/j.ejpb.2021.11.007
Jansen, E. M., Frijlink, H. W., Hinrichs, W. L. J., & Ruigrok, M. J. R. (2022). Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert Opinion on Drug Delivery, 19(11), 1471-1485. https://doi.org/10.1080/17425247.2022.2131767
Heida, R., Born, P. A., Tapia-Calle, G., Frijlink, H. W., Salvati, A., Huckriede, A. L. W., & Hinrichs, W. L. J. (2022). Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro. Pharmaceuticals, 15(7), Article 887. https://doi.org/10.3390/ph15070887
Nguyen, K. T. T., Heijningen, F. F. M., Zillen, D., van Bommel, K. J. C., van Ee, R. J., Frijlink, H. W., & Hinrichs, W. L. J. (2022). Formulation of a 3D Printed Biopharmaceutical: The Development of an Alkaline Phosphatase Containing Tablet with Ileo-Colonic Release Profile to Treat Ulcerative Colitis. Pharmaceutics, 14(10), Article 2179. https://doi.org/10.3390/pharmaceutics14102179
Tian, Y., Lee, J., van der Maaden, K., Bhide, Y., de Vries-Idema, J. J., Akkerman, R., O'Mahony, C., Jiskoot, W., Frijlink, H. W., Huckriede, A. L. W., Hinrichs, W. L. J., Bouwstra, J. A., & Beukema, M. (2022). Intradermal Administration of Influenza Vaccine with Trehalose and Pullulan-Based Dissolving Microneedle Arrays. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2022.01.033
Woerdenbag, H. J., Visser, J. C., Leferink Op Reinink, M. P. A. M., van Orsoy, R. R., Eissens, A. C., Hagedoorn, P., Dijkstra, H., Allersma, D. P., Ng, S. W., Smeets, O. S. N. M., & Frijlink, H. W. (2022). Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised Medication with Tablets. Pharmaceutics, 14(2), Article 320. https://doi.org/10.3390/pharmaceutics14020320
Ruigrok, M. J. R., Roest, M. A. P., Frijlink, H. W., Olinga, P., Hinrichs, W. L. J., & Melgert, B. N. (2022). RANKL confers protection against cell death in precision-cut lung slices. Frontiers in Physiology, 13, Article 1029697. https://doi.org/10.3389/fphys.2022.1029697
de Reus, Y. A., Hagedoorn, P., Sturkenboom, M. G. G., Grasmeijer, F., Bolhuis, M. S., Sibum, I., Kerstjens, H. A. M., Frijlink, H. W., & Akkerman, O. W. (2022). Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. PLoS ONE, 17(8), Article e0272034. https://doi.org/10.1371/journal.pone.0272034

2021

Heida, R., Hinrichs, W. L. J., & Frijlink, H. W. (2022). Inhaled vaccine delivery in the combat against respiratory viruses: A 2021 overview of recent developments and implications for COVID-19. Expert review of vaccines, 21(7), 957-974. https://doi.org/10.1080/14760584.2021.1903878
Larmené-Beld, K., Wijnsma, R., Kuiper, A., van Berkel, S., Robben, H., Taxis, K., & Frijlink, H. (2022). Science- and risk-based strategy to qualify prefillable autoclavable syringes as primary packaging material. European Journal of Hospital Pharmacy: Science and Practice, 29(5), 248-254. https://doi.org/10.1136/ejhpharm-2020-002333
Broesder, A., Bircan, S. Y., De Waard, A. B., Eissens, A. C., Frijlink, H. W., & Hinrichs, W. L. J. (2021). Formulation and in vitro evaluation of pellets containing sulfasalazine and caffeine to verify ileo-colonic drug delivery. Pharmaceutics, 13(12), Article 1985. https://doi.org/10.3390/pharmaceutics13121985
Ruigrok, M. J. R., Frijlink, H. W., Melgert, B. N., Olinga, P., & Hinrichs, W. L. J. (2021). Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Molecular Therapy - Methods & Clinical Development, 20, 483-496. https://doi.org/10.1016/j.omtm.2021.01.003
Broesder, A., Berends, J. M. E., Scheepers, S. M., Nguyen, D. N., Frijlink, H. W., & Hinrichs, W. L. J. (2021). Ileo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems. Pharmaceutics, 13(5). https://doi.org/10.3390/pharmaceutics13050731
Gareb, B., Beugeling, M., Posthumus, S., Otten, A. T., Dijkstra, G., Kosterink, J. G. W., & Frijlink, H. W. (2021). Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease. Journal of drug delivery science and technology, 64, Article 102552. https://doi.org/10.1016/j.jddst.2021.102552
van der Kooij, R. S., Steendam, R., Zuidema, J., Frijlink, H. W., & Hinrichs, W. L. J. (2021). Microfluidic Production of Polymeric Core-Shell Microspheres for the Delayed Pulsatile Release of Bovine Serum Albumin as a Model Antigen. Pharmaceutics, 13(11), Article 1854. https://doi.org/10.3390/pharmaceutics13111854
Zillen, D., Beugeling, M., Hinrichs, W. L. J., Frijlink, H. W., & Grasmeijer, F. (2021). Natural and bioinspired excipients for dry powder inhalation formulations. Current Opinion in Colloid and Interface Science, 56, Article 101497. https://doi.org/10.1016/j.cocis.2021.101497
Ruigrok, M. J. R., El Amasi, K. E. M., Leeming, D. J., Sand, J. M. B., Frijlink, H. W., Hinrichs, W. L. J., & Olinga, P. (2021). Silencing Heat Shock Protein 47 (HSP47) in Fibrogenic Precision-Cut Lung Slices: A Surprising Lack of Effects on Fibrogenesis? Frontiers in Medicine, 8, Article 607962. https://doi.org/10.3389/fmed.2021.607962

2020

Heida, R., Bhide, Y. C., Gasbarri, M., Kocabiyik, Ö., Stellacci, F., Huckriede, A. L. W., Hinrichs, W. L. J., & Frijlink, H. W. (2021). Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discovery Today, 26(1), 122-137. https://doi.org/10.1016/j.drudis.2020.10.009
Akkerman-Nijland, A. M., Akkerman, O. W., Grasmeijer, F., Hagedoorn, P., Frijlink, H. W., Rottier, B. L., Koppelman, G. H., & Touw, D. J. (2021). The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opinion on Drug Metabolism & Toxicology, 17(1), 53-68. https://doi.org/10.1080/17425255.2021.1836157
Hagedoorn, P., Bawary, W., Frijlink, H. W., & Grasmeijer, F. (2020). A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers. The Journal of Allergy and Clinical Immunology: In Practice, 8(3), 1124-1125.e4. https://doi.org/10.1016/j.jaip.2019.09.021
Sibum, I., Hagedoorn, P., Botterman, C. O., Frijlink, H. W., & Grasmeijer, F. (2020). Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops(R)High Dose Dry Powder Inhalation Device While Maintaining Dispersibility. Pharmaceutics, 12(7), 1-14. Article 645. https://doi.org/10.3390/pharmaceutics12070645
Akkerman-Nijland, A. M., Grasmeijer, F., Kerstjens, H. A. M., Frijlink, H. W., van der Vaart, H., Vonk, J. M., Hagedoorn, P., Rottier, B. L., Koppelman, G. H., & Akkerman, O. W. (2020). Colistin dry powder inhalation with the Twincer (TM): An effective and more patient friendly alternative to nebulization. PLoS ONE, 15(9), Article e0239658. https://doi.org/10.1371/journal.pone.0239658
Hagedoorn, P., Grasmeijer, F., Bawari, W., Frijlink, H. W., & Grasmeijer, F. (2020). Comparing five antistatic valved holding chambers: How antistatic are they really? European Respiratory Journal, 56. https://doi.org/10.1183/13993003.congress-2020.3177
Gareb, B., Dijkstra, G., Kosterink, J. G. W., & Frijlink, H. W. (2020). De ontwikkeling van budesonidetabletten met nulde-orde-afgifte voor de behandeling van ileo-colonische inflammatoire darmziekten en vergelijking met huidige, commerciële preparaten. Pharmaceutisch Weekblad, 155(6), 29-36. https://www.npfo.nl/artikel/de-ontwikkeling-van-budesonidetabletten-met-nulde-orde-afgifte-voor-de-behandeling-van-ileo
Tian, Y., Bhide, Y. C., Woerdenbag, H. J., Huckriede, A. L. W., Frijlink, H. W., Hinrichs, W. L. J., & Visser, J. C. (2020). Development of an Orodispersible Film Containing Stabilized Influenza Vaccine. Pharmaceutics, 12(3), Article 245. https://doi.org/10.3390/pharmaceutics12030245
Weerts, Z. Z. R. M., Masclee, A. A. M., Witteman, B. J. M., Clemens, C. H. M., Winkens, B., Brouwers, J. R. B. J., Frijlink, H. W., Muris, J. W. M., De Wit, N. J., Essers, B. A. B., Tack, J., Snijkers, J. T. W., Bours, A. M. H., de Ruiter-van der Ploeg, A. S., Jonkers, D. M. A. E., & Keszthelyi, D. (2020). Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology, 158(1), 123-136. Article 158. https://doi.org/10.1053/j.gastro.2019.08.026
Akkerman-Nijland, A. M., Yousofi, M., Rottier, B. L., Van der Vaart, H., Burgerhof, J. G. M., Frijlink, H. W., Touw, D. J., Koppelman, G. H., & Akkerman, O. W. (2020). Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin. Therapeutic advances in respiratory disease, 14, Article 1753466620905279. https://doi.org/10.1177/1753466620905279
Pleguezuelos, O., Dille, J., de Groen, S., Oftung, F., Niesters, H. G. M., Islam, M. A., Naess, L. M., Hungnes, O., Aldarij, N., Idema, D. L., Perez, A. F., James, E., Frijlink, H. W., Stoloff, G., Groeneveld, P., & Hak, E. (2020). Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults. Annals of Internal Medicine, 172(7), 453-462. https://doi.org/10.7326/M19-0735
Nguyen, K. T. T., Frijlink, H. W., & Hinrichs, W. L. J. (2020). Inhomogeneous Distribution of Components in Solid Protein Pharmaceuticals: Origins, Consequences, Analysis, and Resolutions. Journal of Pharmaceutical Sciences, 109(1), 134-153. https://doi.org/10.1016/j.xphs.2019.10.010
Ruigrok, M., El-Amasi, K., Frijlink, H. W., Hinrichs, W., & Olinga, P. (2020). Knockdown of heat shock protein 47 (HSP47) and its effects on fibrogenesis. Poster session presented at Keystone Symposia on Fibrosis and Tissue Repair, Victoria, Canada.
Sibum, I., Grasmeijer, F., Hagedoorn, P., & Frijlink, H. W. (2020). Optimisation of an isoniazid dry powder formulation for pulmonary administration. Journal of aerosol medicine and pulmonary drug delivery, 33(2), A2-A2.
Broesder, A., Woerdenbag, H. J., Prins, G. H., Nguyen, D. N., Frijlink, H. W., & Hinrichs, W. L. J. (2020). pH-dependent ileocolonic drug delivery, part I: in vitro and clinical evaluation of novel systems. Drug Discovery Today, 25(8), 1362-1373. https://doi.org/10.1016/j.drudis.2020.06.011
Broesder, A., Kosta, A.-M. M. A. C., Woerdenbag, H. J., Nguyen, D. N., Frijlink, H. W., & Hinrichs, W. L. J. (2020). pH-dependent ileocolonic drug delivery, part II: Preclinical evaluation of novel drugs and novel excipients. Drug Discovery Today, 25(8), 1374-1388. https://doi.org/10.1016/j.drudis.2020.06.012
Larmene-Beld, K. H. M., van Berkel, S., Wijnsma, R., Taxis, K., & Frijlink, H. W. (2020). Prefilled Cyclic Olefin Sterilized Syringes of Norepinephrine Injection Solution Do Not Need to Be Stabilized by Antioxidants. Aaps pharmscitech, 21(7), 247. Article 247. https://doi.org/10.1208/s12249-020-01784-z
Hagedoorn, P., Bawary, W., Frijlink, H. W., & Grasmeijer, F. (2020). Relative lung dose from antistatic valved holding chambers Reply. The Journal of Allergy and Clinical Immunology: In Practice, 8(3), 1166-1167. https://doi.org/10.1016/j.jaip.2019.11.023
Gareb, B., Otten, A. T., Frijlink, H. W., Dijkstra, G., & Kosterink, J. G. W. (2020). Review: Local Tumor Necrosis Factor-alpha Inhibition in Inflammatory Bowel Disease. Pharmaceutics, 12(6), 1-31. Article 539. https://doi.org/10.3390/pharmaceutics12060539
Gerritsen, J., Bloemers, J., van Rooij, K., de Leede, L., van der Geest, R., Frijlink, H. W., Koppeschaar, H. P. F., Olivier, B., & Tuiten, A. (2020). The Effect of Food on the Pharmacokinetics of Buspirone After Single Administration of a Sublingual Testosterone and Oral Buspirone Combination Tablet in Healthy Female Subjects. Sexual medicine, 8(2), 186-194. https://doi.org/10.1016/j.esxm.2020.01.005

2019

Busscher, H. J., Woudstra, W., van Kooten, T. G., Jutte, P., Shi, L., Liu, J., Hinrichs, W. L. J., Frijlink, H. W., Shi, R., Liu, J., Parvizi, J., Kates, S., Rotello, V. M., Schaer, T. P., Williams, D., Grainger, D. W., & van der Mei, H. C. (2020). Accepting higher morbidity in exchange for sacrificing fewer animals in studies developing novel infection-control strategies. Biomaterials, 232, Article 119737. https://doi.org/10.1016/j.biomaterials.2019.119737
Sibum, I., Hagedoorn, P., Kluitman, M. P. G., Kloezen, M., Frijlink, H. W., & Grasmeijer, F. (2020). Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine. Pharmaceutics, 12(1), Article 24. https://doi.org/10.3390/pharmaceutics12010024
Yska, J. P., Wanders, J. T. M., Odigie, B., Apers, J. A., Emous, M., Totté, E. R. E., Boerma, E. C., Ubels, F. L., Woerdenbag, H. J., Frijlink, H. W., Wilffert, B., & Van Roon, E. N. (2020). Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: A single oral dose study before and after surgery. European Journal of Hospital Pharmacy: Science and Practice, 27(E1), e19–e24. https://doi.org/10.1136/ejhpharm-2018-001804
Boudewijn, I. M., Lan, A., Faiz, A., Cox, C. A., Brouwer, S., Schokker, S., Vroegop, S. J., Nawijn, M. C., Woodruff, P. G., Christenson, S. A., Hagedoorn, P., Frijlink, H. W., Choy, D. F., Brouwer, U., Wisman, M., Postma, D. S., Fingleton, J., Beasley, R., van den Berge, M., & Guryev, V. (2020). Nasal gene expression changes with inhaled corticosteroid treatment in asthma. Allergy, 75(1), 191-194. https://doi.org/10.1111/all.13952
Yska, J. P., Punter, R. J., Woerdenbag, H. J., Emous, M., Frijlink, H. W., Wilffert, B., & Van Roon, E. N. (2019). A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass. European Journal of Hospital Pharmacy: Science and Practice, 26(3), 152-156. https://doi.org/10.1136/ejhpharm-2017-001360
Cox, C. A., Boudewijn, I. M., Vroegop, S. J., Schokker, S., Lexmond, A. J., Frijlink, H. W., Hagedoorn, P., Vonk, J. M., Farenhorst, M. P., ten Hacken, N. H. T., Kerstjens, H. A. M., & van den Berge, M. (2019). Associations of AMP and adenosine induced dyspnea sensation to large and small airways dysfunction in asthma. BMC Pulmonary Medicine, 19(1), Article 23. https://doi.org/10.1186/s12890-019-0783-0
Larmené-Beld, K. H. M., Frijlink, H. W., & Taxis, K. (2019). A systematic review and meta-analysis of microbial contamination of parenteral medication prepared in a clinical versus pharmacy environment. European Journal of Clinical Pharmacology, 75(5), 609-617. https://doi.org/10.1007/s00228-019-02631-2
Sibum, I., Hagedoorn, P., Frijlink, H. W., & Grasmeijer, F. (2019). Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation. Pharmaceutics, 11(5), Article 233. https://doi.org/10.3390/pharmaceutics11050233
Janssen, R., Wouters, E. F. M., Janssens, W., Daamen, W. F., Hagedoorn, P., de Wit, H. A. J. M., Serre, J., Gayan-Ramirez, G., Franssen, F. M. E., Reynaert, N. L., von der Thusen, J. H., & Frijlink, H. W. (2019). Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale. International Journal of Chronic Obstructive Pulmonary Disease, 14, 2587-2602. https://doi.org/10.2147/COPD.S228411
Beugeling, M., Amssoms, K., Cox, F., De Clerck, B., Van Gulck, E., Verwoerd, J., Kraus, G., Roymans, D., Baert, L., Frijlink, H. W., & Hinrichs, W. (2019). Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. Pharmaceutics, 11(10), Article 510. https://doi.org/10.3390/pharmaceutics11100510
Sibum, I., Grasmeijer, F., Hagedoorn, P., & Frijlink, H. W. (2019). Formulating Amikacin for dry powder inhalation. Journal of aerosol medicine and pulmonary drug delivery, 32(2), A7-A7. https://doi.org/10.1089/jamp.2019.ab01.abstracts
Luinstra, M., Isufi, V., de Jong, L., Rutgers, A. W. F., Hagedoorn, P., Puttenstein, J., van Laar, T., & Frijlink, H. W. (2019). Learning from Parkinson's patients: Usability of the Cyclops dry powder inhaler. International Journal of Pharmaceutics, 567, 118493. Article 118493. https://doi.org/10.1016/j.ijpharm.2019.118493
Tian, Y., Orlu, M., Woerdenbag, H. J., Scarpa, M., Kiefer, O., Kottke, D., Sjoholm, E., Oblom, H., Sandler, N., Hinrichs, W. L. J., Frijlink, H. W., Breitkreutz, J., & Visser, J. C. (2019). Oromucosal films: from patient centricity to production by printing techniques. Expert Opinion on Drug Delivery, 16(9), 981-993. https://doi.org/10.1080/17425247.2019.1652595
Beugeling, M., Born, P., Amssoms, K., De Clerck, B., Van Gulck, E., Frijlink, H. W., Grasmeijer, N., Kraus, G., Baert, L., & Hinrichs, W. (2019). Ovalbumin-Containing Core-Shell Implants Suitable to Obtain a Delayed IgG1 Antibody Response in Mice. Poster session presented at AAPS PharmSci 360, San Antonio, United States.
Luinstra, M., Rutgers, W., van Laar, T., Grasmeijer, F., Begeman, A., Isufi, V., Steenhuis, L., Hagedoorn, P., de Boer, A., & Frijlink, H. W. (2019). Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Therapeutic advances in chronic disease, 10. https://doi.org/10.1177/2040622319857617
Tian, Y., Visser, C., Woerdenbag, H., Frijlink, H. W., & Hinrichs, W. (2019). Printing biopharmaceuticals onto orodispersible films. Poster session presented at AAPS PharmSci 360, San Antonio, United States.
Tomar, J., Tonnis, W. F., Patil, H. P., de Boer, A. H., Hagedoorn, P., Vanbever, R., Frijlink, H. W., & Hinrichs, W. L. J. (2019). Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination. Acta Pharmaceutica Sinica B, 9(6), 1231-1240. https://doi.org/10.1016/j.apsb.2019.05.003
Beugeling, M., De Zee, J., Woerdenbag, H. J., Frijlink, H. W., Wilschut, J. C., & Hinrichs, W. L. J. (2019). Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly. Expert review of vaccines, 18(9), 935-950. https://doi.org/10.1080/14760584.2019.1657013
van Dijk, F., Teekamp, N., Post, E., Schuppan, D., Kim, Y. O., Zuidema, J., Steendam, R., Klose, M. H. M., Meier-Menches, S. M., Casini, A., Horvatovich, P. L., Sijbrandi, N. J., Frijlink, H. W., Hinrichs, W. L. J., Poelstra, K., Beljaars, L., & Olinga, P. (2019). The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor. Journal of Controlled Release, 296, 250-257. https://doi.org/10.1016/j.jconrel.2018.12.039
Bloemers, J., Gerritsen, J., van Rooij, K., de Leede, L., van der Geest, R., Frijlink, H. W., Koppeschaar, H. P. F., Olivier, B., & Tuiten, A. (2019). The Effect of Food on the Pharmacokinetics of Sildenafil after Single Administration of a Sublingual Testosterone and Oral Sildenafil Combination Tablet in Healthy Female Subjects. Journal of Sexual Medicine, 16(9), 1433-1443. https://doi.org/10.1016/j.jsxm.2019.06.015
Ruigrok, M., Tomar, J., Frijlink, H. W., Melgert, B., Hinrichs, W., & Olinga, P. (2019). The effects of oxygen concentration on cell death, anti-oxidant transcription, acute inflammation, and cell proliferation in precision-cut lung slices. Scientific Reports, 9(1), Article 16239. https://doi.org/10.1038/s41598-019-52813-2
Beugeling, M., Grasmeijer, N., Born, P., van der Meulen, M., Kooij, van der, R., Schwengle, K., Baert, L., Amssoms, K., Frijlink, H. W., & Hinrichs, W. (2019). The Mechanism Behind the Biphasic Pulsatile Drug Release from Physically Mixed Poly(DL-Lactic(-Co-Glycolic) Acid)-Based Compacts. Poster session presented at AAPS PharmSci 360, San Antonio, United States.
Gareb, B., Posthumus, S., Beugeling, M., Koopmans, P., Touw, D. J., Dijkstra, G., Kosterink, J. G. W., & Frijlink, H. W. (2019). Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics, 11(9), Article 428. https://doi.org/10.3390/pharmaceutics11090428
Murti, Y. B., Hartini, Y. S., Hinrichs, W. L. J., Frijlink, H. W., & Setyaningsih, D. (2019). UV-Vis spectroscopy to enable determination of the dissolution behavior of solid dispersions containing curcumin and piperine. Journal of Young Pharmacists, 11(1), 26-30. https://doi.org/10.5530/jyp.2019.11.6
Frijlink, H. W. (2019). Wisselen van medicijnen.

2018

Gareb, B., Dijkstra, G., Kosterink, J. G. W., & Frijlink, H. W. (2019). Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. International Journal of Pharmaceutics, 554, 366-375. https://doi.org/10.1016/j.ijpharm.2018.11.019
Grasmeijer, N., Tiraboschi, V., Woerdenbag, H. J., Frijlink, H. W., & Hinrichs, W. L. J. (2019). Identifying critical process steps to protein stability during spray drying using a vibrating mesh or a two-fluid nozzle. European Journal of Pharmaceutical Sciences, 128, 152-157. https://doi.org/10.1016/j.ejps.2018.11.027
Tomar, J., Patil, H. P., Bracho, G., Tonnis, W. F., Frijlink, H. W., Petrovsky, N., Vanbever, R., Huckriede, A., & Hinrichs, W. L. J. (2018). Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. Journal of Controlled Release, 288, 199-211. https://doi.org/10.1016/j.jconrel.2018.09.006
Weerts, Z. Z. R. M., Keszthelyi, D., Vork, L., Aendekerk, N. C. P., Frijlink, H. W., Brouwers, J. R. B. J., Neef, C., Jonkers, D. M. A. E., & Masclee, A. A. M. (2018). A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Advances in therapy, 35(11), 1965-1978. https://doi.org/10.1007/s12325-018-0802-1
Sibum, I., Hagedoorn, P., de Boer, A. H., Frijlink, H. W., & Grasmeijer, F. (2018). Challenges for pulmonary delivery of high powder doses. International Journal of Pharmaceutics, 548(1), 325-336. https://doi.org/10.1016/j.ijpharm.2018.07.008
Akkerman, O. W., Grasmeijer, F., de Lange, W. C. M., Kerstjens, H. A. M., de Vries, G., Bolhuis, M. S., Alffenaar, J.-W., Frijlink, H. W., Smith, G., Gajraj, R., de Zwaan, R., Hagedoorn, P., Dedicoat, M., van Soolingen, D., & van der Werf, T. S. (2018). Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. European Respiratory Journal, 51(3), Article 1702490. https://doi.org/10.1183/13993003.02490-2017
Kanojia, G., Raeven, R. H. M., van der Maas, L., Bindels, T. H. E., van Riet, E., Metz, B., Soema, P. C., Ten Have, R., Frijlink, H. W., Amorij, J.-P., & Kersten, G. F. A. (2018). Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization. Journal of controlled release : official journal of the Controlled Release Society, 286, 167-178. https://doi.org/10.1016/j.jconrel.2018.07.035
Tuiten, A., van Rooij, K., Bloemers, J., Eisenegger, C., van Honk, J., Kessels, R., Kingsberg, S., Derogatis, L. R., de Leede, L., Gerritsen, J., Koppeschaar, H. P. F., Olivier, B., Everaerd, W., Frijlink, H. W., Höhle, D., de Lange, R. P. J., Böcker, K. B. E., & Pfaus, J. G. (2018). Efficacy and safety of on-demand use of 2 treatments designed for different etiologies of female sexual interest/arousal disorder: 3 Randomized Clinical Trials. Journal of Sexual Medicine, 15(2), 201-216. https://doi.org/10.1016/j.jsxm.2017.11.226
Kauppinen, A., Broekhuis, J., Grasmeijer, N., Tonnis, W., Ketolainen, J., Frijlink, H. W., & Hinrichs, W. L. J. (2018). Efficient production of solid dispersions by spray drying solutions of high solid content using a 3-fluid nozzle. European Journal of Pharmaceutics and Biopharmaceutics, 123, 50-58. https://doi.org/10.1016/j.ejpb.2017.11.009
Sibum, I., Grasmeijer, F., Hagedoorn, P., & Frijlink, H. W. (2018). FORMULATING ISONIAZID FOR DRY POWDER INHALATION BY SPRAY DRYING. Journal of aerosol medicine and pulmonary drug delivery, 31(2), A2-A2.
Broesder, A., Teekamp, N., van Dijk, F., Beljaars, E., Hinrichs, W., Poelstra, K., Frijlink, H. W., & Olinga, P. (2018). Formulation of biodegradable microspheres for the sustained release of PDGFβ-receptor directed HSA targeted to fibrotic tissue. Poster session presented at 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spain.
Tuiten, A., Michiels, F., Böcker, K. B., Höhle, D., van Honk, J., de Lange, R. P., van Rooij, K., Kessels, R., Bloemers, J., Gerritsen, J., Janssen, P., de Leede, L., Meyer, J.-J., Everaerd, W., Frijlink, H. W., Koppeschaar, H. P., Olivier, B., & Pfaus, J. G. (2018). Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial. Women's health (London, England), 14. https://doi.org/10.1177/1745506518788970
Frijlink, H. W. (2018). Moeiteloos inhaleren. New scientist, (Special 'Engineering in Groningen'), 28-29.
Tian, Y., Visser, J. C., Klever, J. S., Woerdenbag, H. J., Frijlink, H. W., & Hinrichs, W. L. J. (2018). Orodispersible films based on blends of trehalose and pullulan for protein delivery. European Journal of Pharmaceutics and Biopharmaceutics, 133, 104-111. https://doi.org/10.1016/j.ejpb.2018.09.016
Amssoms, K., Born, P. A., Beugeling, M., De Clerck, B., Van Gulck, E., Hinrichs, W. L. J., Frijlink, H. W., Grasmeijer, N., Kraus, G., Sutmuller, R., Simmen, K., & Baert, L. (2018). Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice. PLoS ONE, 13(8), e0202961. Article 0202961. https://doi.org/10.1371/journal.pone.0202961
Tomar, J., Biel, C., de Haan, C. A. M., Rottier, P. J. M., Petrovsky, N., Frijlink, H. W., Huckriede, A., Hinrichs, W. L. J., & Peeters, B. (2018). Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge. European Journal of Pharmaceutics and Biopharmaceutics, 133, 85-95. https://doi.org/10.1016/j.ejpb.2018.10.008
Luinstra, M., Rutgers, A. W. F., Vroegop, S. J., Begeman, A., Lexmond, A. J., Grasmeijer, F., Hagedoorn, P., de Boer, A. H., & Frijlink, H. W. (2018). PHARMACOKINETIC EVALUATION AND TOLERABILITY OF INHALED DRY POWDER LEVODOPA IN PARKINSON'S DISEASE PATIENTS. Journal of aerosol medicine and pulmonary drug delivery, 31(2), A9-A9.
Gafar, F., Boudewijn, I. M., Cox, C. A., Vonk, J. M., Schokker, S., Lexmond, A. J., Frijlink, H. W., Hagedoorn, P., Postma, D. S., & van den Berge, M. (2018). Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma. Respiratory Research, 19(1), Article 256. https://doi.org/10.1186/s12931-018-0961-2
Tian, Y., Visser, J. C., Frijlink, H. W., & Woerdenbag, H. (2018). Pullulan and trehalose based films for protein delivery in the oral cavity. Journal of Hepatology.
Bhide, Y., Tomar, J., Dong, W., de Vries-Idema, J., Frijlink, H. W., Huckriede, A., & Hinrichs, W. L. J. (2018). Pulmonary delivery of influenza vaccine formulations in cotton rats: Site of deposition plays a minor role in the protective efficacy against clinical isolate o H1N1pdm virus. Drug Delivery, 25(1), 533-545. https://doi.org/10.1080/10717544.2018.1435748

2017

Lexmond, A. J., Boudewijn, I. M., Hagedoorn, P., Schokker, S., Cox, C. A., Vonk, J. M., ten Hacken, N. H. T., Frijlink, H. W., Vroegop, S. J., & van den Berge, M. (2018). Bronchial Provocation Testing Can Be Improved by Using Dry Powder Adenosine Instead of Nebulized Adenosine Monophosphate. American Journal of Respiratory and Critical Care Medicine, 197(3), 391-394. https://doi.org/10.1164/rccm.201704-0715LE
van Dijk, F., Teekamp, N., Beljaars, L., Post, E., Zuidema, J., Steendam, R., Kim, Y. O., Frijlink, H. W., Schuppand, D., Poelstra, K., Hinrichs, W. L. J., & Olinga, P. (2018). Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver. Journal of Controlled Release, 269, 258-265. https://doi.org/10.1016/j.jconrel.2017.11.029
Last modified:04 September 2024 3.10 p.m.
View this page in: Nederlands